PRESS RELEASE
Floret Center-led research team publishes protocol to examine genetic factors in tuberculosis treatment safety across Africa
The ongoing research is assessing evidence on how genetic differences affect tuberculosis medicine exposure, side effects and treatment outcomes in African populations.
Lagos, Nigeria — — A research team led by Dr Olabisi Flora Davies-Bolorunduro of the Floret Center for Advanced Genomics and Bioinformatics Research has published a systematic review protocol that aims to address an important question in tuberculosis care: how do genetic differences influence the way patients in African populations process and respond to tuberculosis medicines?
Published in Systematic Reviews, the protocol establishes the scientific framework for a review of existing research on genetic variation, antituberculosis drug exposure and treatment-related toxicity. The publication describes the study’s objectives and methods; findings from the review will be reported separately.
Why this research matters
Tuberculosis remains a major public health challenge across Africa. Although standard treatment is effective, patients receiving comparable doses can experience different concentrations of medicine in their bodies. Insufficient exposure may compromise treatment, while excessive exposure can increase the risk of harmful effects, including liver injury. These complications can interrupt treatment and undermine recovery.
Genetic variation is one factor that may help explain these differences. Pharmacogenomics (the study of how a person’s genes influence their response to medicines) offers a way to investigate why treatment may affect patients differently.
Yet African populations remain underrepresented in pharmacogenomic research despite the continent’s extensive genetic diversity and substantial tuberculosis burden. Evidence developed elsewhere may not apply equally across African settings. Differences within Africa also mean that findings from one population cannot automatically be extended to another.
The planned review will bring together and critically assess the available evidence to establish which genetic associations are consistently supported, which remain uncertain and where further research is needed. This is an essential step towards evaluating whether, and under what circumstances, genetic information could help make tuberculosis treatment safer and more effective.
What the review will examine
The researchers will assess studies involving people receiving first- or second-line tuberculosis treatment in African countries. They will examine associations between human genetic variants and medicine concentrations, adverse reactions, treatment interruption and clinical outcomes.
Where sufficient evidence is available, the review will also investigate whether HIV co-infection, diabetes and pregnancy modify these relationships. These considerations are relevant to understanding treatment response in patients whose care may involve additional medicines or physiological changes.
The review will follow Joanna Briggs Institute methodology, with independent reviewers selecting studies, assessing their quality and extracting data. Results will be combined statistically where appropriate, and the certainty of the evidence will be assessed.
Building an evidence base for future care
By distinguishing reliable findings from unresolved questions, the project aims to provide a stronger foundation for future clinical research, the evaluation of personalised dosing approaches and discussions about the appropriate role of genetic testing in tuberculosis care.
The review will not itself establish a new dosing regimen or demonstrate that routine genetic testing should be introduced. Its contribution will be to clarify what the existing evidence can support and what additional studies are required before changes to practice can be justified.
Publishing the protocol makes the planned methods publicly available before the review is completed, supporting transparency and accountability throughout the research process.
The team brings together researchers affiliated with institutions across Africa, Estonia and the United States, including Prof Dru Riddle of the JBI TCU Center for Translational Research in Texas, USA. The collaboration combines African research and healthcare perspectives with expertise in genomics, microbiology, pharmacy and evidence synthesis.
The review is registered in PROSPERO under CRD420261378485.
Publication
Pharmacogenomic determinants of antituberculosis drug exposure and toxicity in African populations: a systematic review protocol.
Journal: Systematic Reviews
Read the protocol:
https://doi.org/10.1186/s13643-026-03380-x
Research and media enquiries
Floret Center for Advanced Genomics and Bioinformatics Research
Email: info@floretcenter.org
ENDS
